ACADIA PHARMACEUTICALS INC — Director's Dealing 2021

Jan 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2021-01-06

Reporting Person: DAVIS STEPHEN (Director, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-06	Common Stock	M	9527	—	Acquired	27966	Direct
2021-01-06	Common Stock	S	3484	$53.34	Disposed	24482	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-06	Restricted Stock Units	$	M	9527	Disposed		Common Stock (9527)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2: Includes 3,653 shares of the Issuer's common stock acquired by the reporting person on November 13, 2020 pursuant to an employee stock purchase program.

F3: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F4: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F5: The restricted stock units vest in four equal annual installments beginning January 6, 2021.